Literature DB >> 31615730

DNA repair inhibitors to enhance radiotherapy: Progresses and limitations.

S Ferreira1, M Dutreix2.   

Abstract

Radiotherapy is one of the most common form of treatment in oncology care. Indeed, radiotherapy proved to be very effective in treating a wide range of malignancies. Nevertheless, certain tumours are intrinsically radioresistant or may evolve to become radioresistant. Resistance to radiotherapy is often associated with dysregulated DNA damage response and repair. Recently, a number of strategies have been developed to improve radiotherapy efficacy by targeting the DNA damage response and repair pathways. Ongoing clinical trials showed the potential of some of these approaches in enhancing radiotherapy, but also highlighted the possible limitations. Here, we will describe (i) the main mechanisms involved in double-strand break repair; (ii) available strategies that target these DNA repair processes to improve radiotherapy and (iii) the clinical outcomes and challenges that have emerged so far.
Copyright © 2019 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ADN; Chemoradiation; Chimioradiothérapie; DNA repair inhibitors; Inhibiteur; Radioresistance; Radiorésistance; Radiosensible; Radiosensitizer; Radiotherapy; Radiotherapy enhancement; Radiothérapie; Réparation

Year:  2019        PMID: 31615730     DOI: 10.1016/j.canrad.2019.08.008

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  5 in total

1.  Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer.

Authors:  Alexander Schramm; Martin Schuler; Clotilde Thumser-Henner; Sebastian Oeck; Sophie Kalmbach; Jan Forster; Franziska Kindl; Ali Sak
Journal:  Cell Death Dis       Date:  2022-06-06       Impact factor: 9.685

2.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

Review 3.  Targeting DNA Repair and Chromatin Crosstalk in Cancer Therapy.

Authors:  Danielle P Johnson; Mahesh B Chandrasekharan; Marie Dutreix; Srividya Bhaskara
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.575

Review 4.  Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy.

Authors:  Sarah Méresse; Mostefa Fodil; Fabrice Fleury; Benoît Chénais
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

5.  Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca2+]m-PDP1-PDH-histone acetylation retrograde signaling.

Authors:  Yingying Shi; You Wang; Huangang Jiang; Xuehua Sun; Hui Xu; Xue Wei; Yan Wei; Guohui Xiao; Zhiyin Song; Fuxiang Zhou
Journal:  Cell Death Dis       Date:  2021-09-06       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.